EmeraMed: who we are…

EmeraMed Limited is a privately held limited liability company (corporation) organized and headquartered in the Republic of Ireland. The Company currently operates in Ireland, Sweden and the United States. The Company’s owner group is primarily composed of physicians, dentists, and patients with personal experience of the product from when it was previously sold as a dietary supplement. If you are interested in learning more about the Company, please use our Contact page to request additional information.

This information is provided for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction.

Emeramide: A unique chelator

Emeramide is a lipophilic, di-thiol metal chelator, and antioxidant. Orphan Drug Designation was received for the treatment of mercury toxicity in the EU and US in 2012. Pre-clinical safety studies, a Phase I trial, and two Phase IIa trials have been performed. The Company is working to obtain marketing authorization in the EU and the US for the treatment of mercury toxicity in both humans and animals. A Phase IIb pivotal study began in October, 2018 in Colombia South America.

  • International Non-Proprietary Name (INN): Emeramide

  • Molecule: N,N’-bis(2-mercaptoethyl)isophthalamide (NBMI)

Our research and development efforts are committed to improving the health and well being of people and animals around the world by applying sound principles of medicine and science and working collaboratively with internationally renowned researchers and university centers.

Meet Our Team

Boyd Haley, PhD
Boyd Haley, PhDChief Scientist & CEO
Over the last two decades Dr. Haley has lectured throughout the world and testified before Congressional oversight committees and the Institute of Medicine regarding various aspects of mercury toxicity and neurological diseases.
Ragnar Klingberg
Ragnar KlingbergVice President
Mr Klingberg has a background in management consulting and as an entrepreneur. Based in Stockholm, Mr Klingberg is arranging preclinical safety studies & upcoming clinical trials. He has been with EmeraMed since 2011.
Kathryn Wachsman
Kathryn WachsmanBoard Secretary
Kathryn Wachsman is a practicing attorney with over three decades of experience in legal advocacy including litigation, mediation, negotiation, and legal analysis. She possesses extensive business experience…
Paul Reicherter, MD
Paul Reicherter, MDBoard Member
Paul Reicherter MD, is a graduate of Baker University in Kansas where he was a scholar athlete and Magna Cum Laude graduate. He earned his medical degree at the University of Kansas Medical Center where he graduated with highest honors and was inducted into the Alpha Omega Alpha Honor Medical Society.
David Kennedy, DDS
David Kennedy, DDSBoard Member
Dr. Kennedy joined the EmeraMed board in June of 2017. He has a BA in Comparative Biochemistry and Physiology from the University of Kansas and a Doctor of Dental Surgery from the University of Missouri. He is the past president of the International Academy of Oral Medicine and Toxicology.

The scientific literature has firmly established that mercury causes a biochemical train wreck especially in the brain where it is linked to a host of neurological illnesses and oxidative stress.

Boyd Haley, PhD, Chief Scientist and CEO


Learn about our company, mission and board of directors.

Early Access

Emeramide has been approved for compassionate use.


Latest News, Research, Clinical Trials, Press and Newsletters.

Discover The Future of Health

We are committed to improving health by way of our unique metal chelator and antioxidant, Emeramide

Contact Us